Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HTGMQ NASDAQ:OLITW NASDAQ:PRENW NYSE:RAL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHTGMQHTG Molecular Diagnostics$0.00$0.00▼$0.02N/A2.671,800 shsN/AOLITWOmniLit Acquisition$0.06-16.4%$0.07$0.01▼$0.23N/AN/A14,538 shs7,342 shsPRENWPrenetics Global$0.04+3.7%$0.02$0.01▼$0.07N/AN/A52,593 shs18,488 shsRALRalliant$46.70-2.7%$0.00$43.75▼$55.08$5.43BN/A4.90 million shs1.51 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHTGMQHTG Molecular Diagnostics0.00%0.00%0.00%0.00%-93.33%OLITWOmniLit Acquisition0.00%-16.44%-27.73%+51.74%-62.32%PRENWPrenetics Global-2.17%+3.75%-13.46%+260.00%+236.45%RALRalliant-3.09%+4,669,999,900.00%+4,669,999,900.00%+4,669,999,900.00%+4,669,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHTGMQHTG Molecular DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AOLITWOmniLit AcquisitionN/AN/AN/AN/AN/AN/AN/AN/APRENWPrenetics GlobalN/AN/AN/AN/AN/AN/AN/AN/ARALRalliantN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHTGMQHTG Molecular Diagnostics 0.00N/AN/AN/AOLITWOmniLit Acquisition 0.00N/AN/AN/APRENWPrenetics Global 0.00N/AN/AN/ARALRalliant 2.50Moderate Buy$58.6725.62% UpsideCurrent Analyst Ratings BreakdownLatest RAL, HTGMQ, OLITW, and PRENW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025RALRalliantEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageIn-Line$52.007/15/2025RALRalliantBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight$60.007/15/2025RALRalliantBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$60.007/15/2025RALRalliantTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.007/14/2025RALRalliantSeaport Res PtnSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHTGMQHTG Molecular Diagnostics$6.37M0.00N/AN/AN/ANaNOLITWOmniLit AcquisitionN/AN/AN/AN/AN/AN/APRENWPrenetics Global$41.52MN/AN/AN/AN/AN/ARALRalliantN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHTGMQHTG Molecular Diagnostics-$21.59MN/A0.00N/AN/AN/AN/AN/AN/AOLITWOmniLit AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/APRENWPrenetics GlobalN/AN/A0.00∞N/AN/AN/AN/AN/ARALRalliantN/AN/A0.00∞2.04N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHTGMQHTG Molecular DiagnosticsN/AN/AN/AN/AN/AOLITWOmniLit AcquisitionN/AN/AN/AN/AN/APRENWPrenetics GlobalN/AN/AN/AN/AN/ARALRalliantN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHTGMQHTG Molecular DiagnosticsN/AOLITWOmniLit AcquisitionN/APRENWPrenetics GlobalN/ARALRalliantN/AInsider OwnershipCompanyInsider OwnershipHTGMQHTG Molecular Diagnostics2.60%OLITWOmniLit AcquisitionN/APRENWPrenetics GlobalN/ARALRalliantN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHTGMQHTG Molecular Diagnostics902.21 million2.16 millionNot OptionableOLITWOmniLit Acquisition3N/AN/ANot OptionablePRENWPrenetics Global1N/AN/ANot OptionableRALRalliant7,000112.99 millionN/AN/ARAL, HTGMQ, OLITW, and PRENW HeadlinesRecent News About These CompaniesRalliant (NYSE:RAL) Coverage Initiated by Analysts at Evercore ISIJuly 18 at 9:32 AM | marketbeat.comRalliant (NYSE:RAL) Raised to "Hold" at Seaport Res PtnJuly 17 at 4:01 AM | americanbankingnews.comRalliant (NYSE:RAL) Coverage Initiated at TD CowenJuly 17 at 4:01 AM | americanbankingnews.comWhat is Seaport Res Ptn's Forecast for Ralliant Q2 Earnings?July 16 at 6:25 AM | marketbeat.comRalliant (NYSE:RAL) Stock Rating Upgraded by BarclaysJuly 16 at 6:01 AM | marketbeat.comTD Cowen Begins Coverage on Ralliant (NYSE:RAL)July 15, 2025 | marketbeat.comRalliant Corporation (NYSE:RAL) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 15, 2025 | marketbeat.comSeaport Res Ptn Upgrades Ralliant (NYSE:RAL) to HoldJuly 15, 2025 | marketbeat.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendBigBear.ai: Why a 90% Rally Could Be Just the StartBy Jeffrey Neal Johnson | July 10, 2025View BigBear.ai: Why a 90% Rally Could Be Just the Start3 Stocks With Near-Unanimous Buys That Could Rally HigherBy Nathan Reiff | July 2, 2025View 3 Stocks With Near-Unanimous Buys That Could Rally Higher3 Upgraded Stocks to Load Up on Before EarningsBy Thomas Hughes | July 8, 2025View 3 Upgraded Stocks to Load Up on Before EarningsRAL, HTGMQ, OLITW, and PRENW Company DescriptionsHTG Molecular Diagnostics NASDAQ:HTGMQHTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.OmniLit Acquisition NASDAQ:OLITW$0.06 -0.01 (-16.44%) As of 07/11/2025OmniLit Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on transactions with companies and/or assets within the photonics or optics, and related sectors. The company was incorporated in 2021 and is based in Miami Beach, Florida.Prenetics Global NASDAQ:PRENW$0.04 +0.00 (+3.75%) Closing price 07/18/2025 11:57 AM EasternExtended Trading$0.04 +0.01 (+16.11%) As of 07/18/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.Ralliant NYSE:RAL$46.70 -1.32 (-2.75%) As of 07/18/2025 03:59 PM EasternRalliant Corporation is a provider of precision technologies which specializes in designing, developing, manufacturing and servicing precision instruments and engineered products. Ralliant Corporation is based in RALEIGH, N.C. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
